Sana Biotechnology (SANA) Projected to Announce Quarterly Earnings on Thursday

Key Points

• Sana Biotechnology is expected to report Q3 2026 earnings after market close on Thursday, November 5. Analysts forecast a loss of $0.1478 per share, with the earnings call scheduled for November 10.
• The company previously reported a quarterly loss of $0.13 per share, beating consensus expectations of a $0.15 loss. Analysts project losses of $0.72 per share for the current fiscal year and $0.61 for the next.
• SANA shares opened at $2.63, near the lower end of their 52-week range, while analyst sentiment remains mixed but leans positive: the stock has a consensus “Moderate Buy” rating and an average price target of $9.33.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) is expected to post its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Sana Biotechnology to post earnings of ($0.1478) per share for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.02. On average, analysts expect Sana Biotechnology to post ($0.72) EPS for the current fiscal year and ($0.61) EPS for the next fiscal year.

Sana Biotechnology Stock Performance

Shares of SANA stock opened at $2.63 on Thursday. The company has a market capitalization of $787.32 million, a P/E ratio of -3.46 and a beta of 2.18. The company's 50 day moving average price is $3.09 and its two-hundred day moving average price is $3.43. Sana Biotechnology has a 52 week low of $2.22 and a 52 week high of $5.58.

Analyst Ratings Changes

SANA has been the subject of several research analyst reports. Bank of America reduced their price target on shares of Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating for the company in a report on Friday, August 14th. TD Cowen upgraded shares of Sana Biotechnology to a "strong-buy" rating in a report on Monday, August 24th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Sana Biotechnology in a research report on Wednesday, October 21st. Finally, Wall Street Zen cut shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $9.33.

About Sana Biotechnology

Sana Biotechnology, Inc is a clinical-stage biotechnology company focused on developing engineered cell and gene therapies for serious diseases. The company's approach is designed to create durable treatments by modifying cells outside or inside the body and using them to replace, repair, or supplement damaged or missing biological functions.

Sana is developing proprietary technologies intended to support the delivery and persistence of therapeutic cells. These include platforms for engineering cells to evade immune-system detection, potentially allowing donor-derived cells to be used without extensive immune suppression, as well as methods for delivering genetic instructions directly to targeted tissues.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.